Innovent Biologics and Daiichi Sankyo Enter Exclusive Agreement for VANFLYTA® Commercialization in China August 11, 2026
Evexta Bio and Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced/Metastatic Breast Cancer August 11, 2026
ACR-2316 advances into dose expansion portion of Ph 1/2 study in SCLC, squamous NSCLC, lung adenocarcinoma (adNSCLC), endometrial, cervical, and GEJ cancers August 11, 2026
IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand August 11, 2026
Sobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphoma August 11, 2026
First Patient Dosed in Registrational Study of IBI363/TAK-928 in Combination with Bevacizumab in Late-Line Advanced CRC in China August 11, 2026
Topline Results from Intranasal NEO100 in Recurrent IDH1-mutant High-grade Glioma to be presented August 11, 2026
CRL issued for ongoing ITM-11 NDA citing CMC and third-party commercial facility inspection-related items August 11, 2026
FDA grants Accelerated Approval to TUDRIQEV + Nivolumab combo for Unresectable Advanced Cutaneous Melanoma After Progression on an anti-PD-1 Based Regimen August 11, 2026
